Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVnCoV Safety and Immunogenicity in Adults with Comorbidities
NCT04860258Phase 3Terminated
- Sponsor
- CureVac
- Start
- Apr 2021
- Primary completion
- Sep 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of zorecimeran in coronavirus disease 2019 (COVID-19), sponsored by CureVac. Started Apr 2021; status: terminated.
02
Drugs
zorecimeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04860258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04860258.